文献速递衰弱、肌少症与跌倒老年慢病共病管理

高龄男性五年骨折风险与五年死亡风险的相关特征

Characteristics Associated With 5-Year Fracture Risk Versus 5-Year Mortality Risk Among Late-Life Men.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2023-01-01

结果显示跌倒史、骨密度和近期骨折是骨折的强预测因素,年龄和多病共存是骨折前死亡的强预测因素,骨折风险与竞争死亡风险仅呈弱相关(r=0.37),提示骨质疏松药物治疗决策需同时考虑骨折风险与预期寿命。

要点

  • 跌倒史、骨密度和近期骨折是高龄男性临床骨折和髋部骨折的强预测因素。
  • 年龄和多病共存是骨折前死亡的强预测因素。
  • 骨折风险与竞争死亡风险仅弱相关(r=0.37),治疗决策应兼顾预期寿命。

核心结论

  • 在高龄男性中,跌倒史、骨密度和近期骨折是临床骨折和髋部骨折的强预测因素;年龄和多病共存是骨折前死亡的强预测因素。
  • 骨质疏松药物治疗决策可通过同时考虑骨折风险与总体预期寿命来进一步优化。

研究设计与样本

  • 采用单独的多变量Fine-Gray竞争风险模型,预设风险因素包括年龄、髋部骨密度、近期骨折(<5年)、跌倒史(既往一年)和多病共存(疾病数量),估计任何临床骨折及临床骨折前死亡的亚分布风险比和绝对5年风险。
  • 次要分析考虑髋部骨折。

主要发现

  • 5年内发生414例临床骨折和595例无骨折前死亡。
  • 骨密度、跌倒史和近期骨折是临床骨折的强预测因素。
  • 年龄和多病共存是骨折前死亡的强预测因素。
  • 在考虑竞争风险后,年龄、骨密度和跌倒史均与髋部骨折及髋部骨折前死亡的风险相关。
  • 模型区分度从0.65(骨折前死亡)到0.79(髋部骨折)不等。

临床怎么用

  • 对高龄男性进行骨折风险评估时,应评估跌倒史、骨密度和近期骨折史。
  • 启动骨质疏松药物治疗前,应同时评估骨折风险和总体预期寿命,尤其关注年龄和多病共存情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Identifying late-life men who might benefit from treatment to prevent fracture is challenging given high mortality. Our objective was to evaluate risks of clinical fracture, hip fracture, and mortality prior to fracture among men aged at least 80 years. METHODS: Study participants included 3 145 community-dwelling men (mean [standard deviation] age 83 [2.8] years) from the Osteoporotic Fractures in Men (MrOS) Study. We used separate multivariable Fine-Gray competing risk models with prespecified risk factors (age, hip bone mineral density [BMD], recent fracture [<5 years], fall history [previous year], and multimorbidity [# conditions]) to estimate subdistribution hazard ratios and absolute 5-year risks of any clinical fracture and mortality prior to clinical fracture. Secondary analysis considered a hip fracture. RESULTS: There were 414 incident clinical fractures and 595 deaths without prior fracture within 5 years. BMD, fall history, and recent fracture were strong predictors of clinical fracture. Age and multimorbidity were strong predictors of mortality before fracture. After accounting for competing risks, age, BMD, and fall history were each associated with both risks of hip fracture and mortality before hip fracture. Model discrimination varied from 0.65 (mortality before fracture) to 0.79 (hip fracture). Estimated mortality differed substantially among men with similar clinical fracture risk due to a modest correlation between fracture risk and competing mortality risk = 0.37. CONCLUSION: In late-life men, strong risk factors for clinical fracture and hip fracture include fall history, BMD, and recent fracture. Osteoporosis drug treatment decisions may be further enhanced by consideration of fracture risk versus overall life expectancy.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Langsetmo L, Schousboe JT, Taylor BC, et al. Characteristics Associated With 5-Year Fracture Risk Versus 5-Year Mortality Risk Among Late-Life Men. J Gerontol A Biol Sci Med Sci. 2023. PMID: 35917212. doi:10.1093/gerona/glac159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。